Negative regulation of human mononuclear phagocyte function

Mucosal Immunology

Volumn 6, Issue 2, 2013, Pages 205-223

  Hedl, M ^a   Abraham, C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; PATTERN RECOGNITION RECEPTOR; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; SH2 CONTAINING INOSITOL 5' PHOSPHATASE; SIGIRR RECEPTOR; SOLUBLE TOLL LIKE RECEPTOR 2; SOLUBLE TOLL LIKE RECEPTOR 4; ST2 RECEPTOR; SUPPRESSOR OF CYTOKINE SIGNALING 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

AUTOCRINE EFFECT; AUTOPHAGY; CELL DIFFERENTIATION; CELL MIGRATION; CELL POLARITY; DOWN REGULATION; EPIGENETICS; EXPERIMENTAL MOUSE; GENE EXPRESSION REGULATION; GENETIC REGULATION; HUMAN; HUMAN VERSUS NONHUMAN DATA; INFLAMMATORY DISEASE; INTESTINAL MACROPHAGE; MACROPHAGE; MACROPHAGE FUNCTION; MACROPHAGE POLARIZATION; MOLECULAR DYNAMICS; MONOCYTE; NEGATIVE REGULATION; NONHUMAN; PARACRINE SIGNALING; PHAGOCYTE DYSFUNCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 84874057230     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2012.139     Document Type: Review

References (362)

1. Abraham, C. & Medzhitov, R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 140, 1729-1737 (2011).
2. Chen, Y., Lui, V.C., Rooijen, N.V. & Tam, P.K. Depletion of intestinal resident macrophages prevents ischaemia reperfusion injury in gut. Gut 53, 1772-1780 (2004).
3. Hunter, M.M. et al. In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. Gastroenterology 138, 1395-1405 (2010).
4. McGaha, T.L., Chen, Y.,Ravishankar, B., van Rooijen, N. &Karlsson, M.C. Marginal zone macrophages suppress innate and adaptive immunity to apoptotic cells in the spleen. Blood 117, 5403-5412 (2011).
5. Rugtveit, J. et al. Respiratory burst of intestinal macrophages in inflammatory bowel disease is mainly caused by CD14+L1+ monocyte derived cells. Gut 37, 367-373 (1995).
6. Lawrence, T. & Natoli, G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat. Rev. Immunol. 11, 750-761 (2011).
7. Hume, D.A. Applications of myeloid-specific promoters in transgenic mice support in vivo imaging and functional genomics but do not support the concept of distinct macrophage and dendritic cell lineages or roles in immunity. J. Leukoc. Biol. 89, 525-538 (2011).
8. Rakoff-Nahoum, S. & Medzhitov, R. Innate immune recognition of the indigenous microbial flora. Mucosal Immunol. 1 (Suppl 1), S10-S14 (2008).
9. Akira, S. & Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499-511 (2004).
10. Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119-124 (2012).
11. Mestas, J. & Hughes, C.C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731-2738 (2004).
12. Davis, M.M. A prescription for human immunology. Immunity 29, 835-838 (2008).
13. Murray, P.J. & Wynn, T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11, 723-737 (2011).
14. Fahy, R.J., Doseff, A.I. & Wewers, M.D. Spontaneous human monocyte apoptosis utilizes a caspase-3-dependent pathway that is blocked by endotoxin and is independent of caspase-1. J. Immunol. 163, 1755-1762 (1999).
15. Becker, S., Warren, M.K. & Haskill, S. Colony-stimulating factor-induced monocyte survival and differentiation into macrophages in serum-free cultures. J. Immunol. 139, 3703-3709 (1987).
16. Foster, S.L., Hargreaves, D.C. & Medzhitov, R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447, 972-978 (2007).
17. Pena, O.M., Pistolic, J., Raj, D., Fjell, C.D. & Hancock, R.E. Endotoxin tolerance represents a distinctive state of alternative polarization (M2) in human mononuclear cells. J. Immunol. 186, 7243-7254 (2011).
18. Randow, F. et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J. Exp. Med. 181, 1887-1892 (1995).
19. Fan, H. & Cook, J.A. Molecular mechanisms of endotoxin tolerance. J. Endotoxin. Res. 10, 71-84 (2004).
20. Medvedev, A.E., Lentschat, A.,Wahl, L.M., Golenbock, D.T. & Vogel, S.N. Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin- tolerant cells. J. Immunol. 169, 5209-5216 (2002).
21. Medvedev, A.E., Kopydlowski, K.M. & Vogel, S.N. Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression. J. Immunol. 164, 5564-5574 (2000).
22. Nomura, F. et al. Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J. Immunol. 164, 3476-3479 (2000).
23. Adib-Conquy, M. & Cavaillon, J.M. Gamma interferon and granulocyte/monocyte colony-stimulating factor prevent endotoxin tolerance in human monocytes by promoting interleukin-1 receptor-associated kinase expression and its association to MyD88 and not by modulating TLR4 expression. J. Biol. Chem. 277, 27927-27934 (2002).
24. Medvedev, A.E. et al. Induction of tolerance to lipopolysaccharide and mycobacterial components in Chinese hamster ovary/CD14 cells is not affected by overexpression of Toll-like receptors 2 or 4. J. Immunol. 167, 2257-2267 (2001).
25. Smith, P.D. et al. Intestinal macrophages and response to microbial encroachment. Mucosal Immunol. 4, 31-42 (2011).
26. Smythies, L.E. et al. Inflammation anergy in human intestinal macrophages is due to Smad-induced IkappaBalpha expression and NF-kappaB inactivation. J. Biol. Chem. 285, 19593-19604 (2010).
27. Cario, E. & Podolsky, D.K. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect. Immun. 68, 7010-7017 (2000).
28. Fukata, M. et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133, 1869-1881 (2007).
29. Fukata, M. et al. Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm. Bowel Dis. 17, 1464-1473 (2010).
30. Vig, E. et al. Modulation of tumor necrosis factor and interleukin-1- dependent NF-kappaB activity by mPLK/IRAK. J. Biol. Chem. 274, 13077-13084 (1999).
31. Hedl, M., Li, J., Cho, J.H. & Abraham, C. Chronic stimulation of Nod2 mediates tolerance to bacterial products. Proc. Natl. Acad. Sci. USA 104, 19440-19445 (2007).
32. Lotz, M. et al. Postnatal acquisition of endotoxin tolerance in intestinal epithelial cells. J. Exp. Med. 203, 973-984 (2006).
33. Suzuki, N. et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 416, 750-756 (2002).
34. Toubiana, J. et al. IRAK1 functional genetic variant affects severity of septic shock. Crit. Care Med. 38, 2287-2294 (2010).
35. Arcaroli, J. et al. Variant IRAK-1 haplotype is associated with increased nuclear factor-kappaB activation and worse outcomes in sepsis. Am. J. Respir. Crit. Care Med. 173, 1335-1341 (2006).
36. Picard, C. et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore) 89, 403-425 (2010).
37. Sha,W.C., Liou, H.C., Tuomanen, E.I. & Baltimore, D. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 80, 321-330 (1995).
38. Kang, S.M., Tran, A.C., Grilli, M. & Lenardo, M.J. NF-kappa B subunit regulation in nontransformed CD4+ T lymphocytes. Science 256, 1452-1456 (1992).
39. Oeckinghaus, A., Hayden, M.S. & Ghosh, S. Crosstalk in NF-kappaB signaling pathways. Nat. Immunol. 12, 695-708 (2011).
40. Tomczak, M.F. et al. NF-kappa B is required within the innate immune system to inhibit microflora-induced colitis and expression of IL-12 p40. J. Immunol. 171, 1484-1492 (2003).
41. Bohuslav, J. et al. Regulation of an essential innate immune response by the p50 subunit of NF-kappaB. J. Clin. Invest. 102, 1645-1652 (1998).
42. Porta, C. et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc. Natl. Acad. Sci. USA 106, 14978-14983 (2009).
43. Greten, F.R. et al. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 130, 918-931 (2007).
44. Erdman, S., Fox, J.G., Dangler, C.A., Feldman, D. & Horwitz, B.H. Typhlocolitis in NF-kappa B-deficient mice. J. Immunol. 166, 1443-1447 (2001).
45. Neurath, M.F., Pettersson, S., Meyer zum Buschenfelde, K.H. & Strober, W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat. Med. 2, 998-1004 (1996).
46. Guma, M. et al. Constitutive intestinal NF-kappaB does not trigger destructive inflammation unless accompanied by MAPK activation. J. Exp. Med. 208, 1889-1900 (2011).
47. Ishikawa, H. et al. Chronic inflammation and susceptibility to bacterial infections in mice lacking the polypeptide (p)105 precursor (NF-kappaB1) but expressing p50. J. Exp. Med. 187, 985-996 (1998).
48. Sampath, V. et al. The NFKB1 (g.-24519delATTG) variant is associated with necrotizing enterocolitis (NEC) in premature infants. J. Surg. Res. 169, e51-e57 (2011).
49. Neurath, M.F. et al. Cytokine gene transcription by NF-kappa B family members in patientswith inflammatory bowel disease. Ann. NYAcad. Sci. 859, 149-159 (1998).
50. Rogler, G. et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115, 357-369 (1998).
51. Litvak, V. et al. Function of C/EBPdelta in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals. Nat. Immunol. 10, 437-443 (2009).
52. Brint, E.K. et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat. Immunol. 5, 373-379 (2004).
53. Sweet, M.J. et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J. Immunol. 166, 6633-6639 (2001).
54. Takezako, N. et al. ST2 suppresses IL-6 production via the inhibition of IkappaB degradation induced by the LPS signal in THP-1 cells. Biochem. Biophys. Res. Commun. 341, 425-432 (2006).
55. Dinarello,C.A. An IL-1 familymember requires caspase-1 processing and signals through the ST2 receptor. Immunity 23, 461-462 (2005).
56. Pastorelli, L. et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc. Natl. Acad. Sci. USA 107, 8017-8022 (2010).
57. Coyle, A.J. et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J. Exp. Med. 190, 895-902 (1999).
58. Seidelin, J.B., Rogler, G. & Nielsen, O.H. A role for interleukin-33 in T(H)2- polarized intestinal inflammation?. Mucosal Immunol. 4, 496-502 (2011).
59. Franke, A. et al. Genome-widemeta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 42, 1118-1125 (2010).
60. Kobayashi, K. et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110, 191-202 (2002).
61. Park, S.H., Park-Min, K.H., Chen, J., Hu, X. & Ivashkiv, L.B. Tumor necrosis factor induces GSK3 kinase-mediated cross-tolerance to endotoxin in macrophages. Nat. Immunol. 12, 607-615 (2011).
62. del Fresno, C. et al. Potent phagocytic activity with impaired antigen presentation identifying lipopolysaccharide-tolerant human monocytes: demonstration in isolated monocytes from cystic fibrosis patients. J. Immunol. 182, 6494-6507 (2009).
63. van't Veer, C. et al. Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J. Immunol. 179, 7110-7120 (2007).
64. Seki, M. et al. Critical role of IL-1 receptor-associated kinase-M in regulating chemokine-dependent deleterious inflammation in murine influenza pneumonia. J. Immunol. 184, 1410-1418 (2010).
65. Biswas, A. et al. Negative regulation of Toll-like receptor signaling plays an essential role in homeostasis of the intestine. Eur. J. Immunol. 41, 182-194 (2011).
66. Balaci, L. et al. IRAK-M is involved in the pathogenesis of early-onset persistent asthma. Am. J. Hum. Genet. 80, 1103-1114 (2007).
67. Nakashima, K. et al. An association study of asthma and related phenotypes with polymorphisms in negative regulator molecules of the TLR signaling pathway. J. Hum. Genet. 51, 284-291 (2006).
68. Nanthakumar, N. et al. The mechanism of excessive intestinal inflammation in necrotizing enterocolitis: an immature innate immune response. PLoS One 6, e177762011).
69. Almeida, A.S. et al. Tuberculosis is associated with a down-modulatory lung immune response that impairs Th1-type immunity. J. Immunol. 183, 718-731 (2009).
70. Endo, T.A. et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387, 921-924 (1997).
71. Starr, R. et al. A family of cytokine-inducible inhibitors of signalling. Nature 387, 917-921 (1997).
72. Nakagawa, R. et al. SOCS-1 participates in negative regulation of LPS responses. Immunity 17, 677-687 (2002).
73. Alexander, W.S. et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98, 597-608 (1999).
74. Prele, C.M. et al. SOCS1 regulates the IFN but not NFkappaB pathway in TLR-stimulated human monocytes and macrophages. J. Immunol. 181, 8018-8026 (2008).
75. Kinjyo, I. et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity 17, 583-591 (2002).
76. Baetz, A., Frey, M., Heeg, K. & Dalpke, A.H. Suppressor of cytokine signaling (SOCS) proteins indirectly regulate toll-like receptor signaling in innate immune cells. J. Biol. Chem. 279, 54708-54715 (2004).
77. Gingras, S., Parganas, E., de Pauw, A., Ihle, J.N. & Murray, P.J. Re-examination of the role of suppressor of cytokine signaling 1 (SOCS1) in the regulation of toll-like receptor signaling. J. Biol. Chem. 279, 54702-54707 (2004).
78. Mostecki, J. et al. A SOCS-1 promoter variant is associated with total serum IgE levels. J. Immunol. 187, 2794-2802 (2011).
79. Harada, M. et al. Functional polymorphism in the suppressor of cytokine signaling 1 gene associated with adult asthma. Am. J. Respir. Cell Mol. Biol. 36, 491-496 (2007).
80. Rothlin, C.V., Ghosh, S., Zuniga, E.I., Oldstone, M.B. & Lemke, G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131, 1124-1136 (2007).
81. Lu, Q. & Lemke, G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 293, 306-311 (2001).
82. Sharif, M.N. et al. Twist mediates suppression of inflammation by type I IFNs and Axl. J. Exp. Med. 203, 1891-1901 (2006).
83. Camenisch, T.D., Koller, B.H., Earp, H.S. & Matsushima, G.K. A novel receptor tyrosine kinase, Mer, inhibits TNF-alpha production and lipopolysaccharide-induced endotoxic shock. J. Immunol. 162, 3498-3503 (1999).
84. Scutera, S. et al. Survival and migration of human dendritic cells are regulated by an IFN-alpha-inducible Axl/Gas6 pathway. J. Immunol. 183, 3004-3013 (2009).
85. Cohen, P.L. et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J. Exp. Med. 196, 135-140 (2002).
86. Scott, R.S. et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 411, 207-211 (2001).
87. Seitz, H.M., Camenisch, T.D., Lemke, G., Earp, H.S. & Matsushima, G.K. Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. J. Immunol. 178, 5635-5642 (2007).
88. Ravichandran, K.S. & Lorenz, U. Engulfment of apoptotic cells: signals for a good meal. Nat. Rev. Immunol. 7, 964-974 (2007).
89. Aadland, E., Odegaard, O.R., Roseth, A. & Try, K. Free protein S deficiency in patients with chronic inflammatory bowel disease. Scand. J. Gastroenterol. 27, 957-960 (1992).
90. Brouwer, J.L., Bijl, M., Veeger,N.J., Kluin-Nelemans, H.C. & van der Meer, J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 104, 143-148 (2004).
91. Lee, E.G. et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 289, 2350-2354 (2000).
92. Wertz, I.E. et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430, 694-699 (2004).
93. Boone, D.L. et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat. Immunol. 5, 1052-1060 (2004).
94. Saitoh, T. et al. A20 is a negative regulator of IFN regulatory factor 3 signaling. J. Immunol. 174, 1507-1512 (2005).
95. Hitotsumatsu, O. et al. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 28, 381-390 (2008).
96. Hammer, G.E. et al. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat. Immunol. 12, 1184-1193 (2011).
97. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678 (2007).
98. Musone, S.L. et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat. Genet. 40, 1062-1064 (2008).
99. Graham, R.R. et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat. Genet. 40, 1059-1061 (2008).
100. Thomson,W. et al. Rheumatoid arthritis association at 6q23. Nat. Genet. 39, 1431-1433 (2007).
101. Plenge,R.M. et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat. Genet. 39, 1477-1482 (2007).
102. Watanabe, T. et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J. Clin. Invest. 118, 545-559 (2008).
103. Negishi, H. et al. Negative regulation of Toll-like-receptor signaling by IRF-4. Proc. Natl. Acad. Sci. USA 102, 15989-15994 (2005).
104. Honma, K. et al. Interferon regulatory factor 4 negatively regulates the production of proinflammatory cytokines by macrophages in response to LPS. Proc. Natl. Acad. Sci. USA 102, 16001-16006 (2005).
105. Mudter, J. et al. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J. Clin. Invest. 118, 2415-2426 (2008).
106. Gabhann, J.N. et al. Absence of SHIP-1 results in constitutive phosphorylation of tank-binding kinase 1 and enhanced TLR3-dependent IFN-beta production. J. Immunol. 184, 2314-2320 (2010).
107. Sly, L.M., Rauh, M.J., Kalesnikoff, J., Song, C.H. & Krystal, G. LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity 21, 227-239 (2004).
108. Rauh, M.J. et al. SHIP represses the generation of alternatively activated macrophages. Immunity 23, 361-374 (2005).
109. Kerr, W.G., Park, M.Y., Maubert, M. & Engelman, R.W. SHIP deficiency causes Crohn's disease-like ileitis. Gut 60, 177-188 (2011).
110. Helgason, C.D. et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 12, 1610-1620 (1998).
111. Arijs, I. et al. Intestinal expression of SHIP in inflammatory bowel diseases. Gut 61, 956-957 (2011).
112. Wang, L. et al. Indirect inhibition of Toll-like receptor and type I interferon responses by ITAM-coupled receptors and integrins. Immunity 32, 518-530 (2010).
113. Kanamaru, Y. et al. Inhibitory ITAM signaling by Fc alpha RI-FcR gamma chain controls multiple activating responses and prevents renal inflammation. J. Immunol. 180, 2669-2678 (2008).
114. Leon, F. et al. Antibodies to complement receptor 3 treat established inflammation inmurinemodels of colitis and a novel model of psoriasiform dermatitis. J. Immunol. 177, 6974-6982 (2006).
115. Bogdan, C., Paik, J., Vodovotz, Y. & Nathan, C. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10. J. Biol. Chem. 267, 23301-23308 (1992).
116. Takeuchi, M., Alard, P. & Streilein, J.W. TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells. J. Immunol. 160, 1589-1597 (1998).
117. Murray, P.J. The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. Proc. Natl. Acad. Sci. USA 102, 8686-8691 (2005).
118. Kontoyiannis, D. et al. Interleukin-10 targets p38MAPKto modulate AREdependent TNF mRNA translation and limit intestinal pathology. Embo J. 20, 3760-3770 (2001).
119. Chan, C.S. et al. Interleukin-10 inhibits LPS induced TNFalpha translation through a SHIP1-dependent pathway. J. Biol. Chem. 287, 38020-38027 (2012).
120. Chang, J., Kunkel, S.L. & Chang, C.H. Negative regulation of MyD88-dependent signaling by IL-10 in dendritic cells. Proc. Natl. Acad. Sci. USA 106, 18327-18332 (2009).
121. Lang, R., Patel, D., Morris, J.J., Rutschman, R.L. & Murray, P.J. Shaping gene expression in activated and resting primary macrophages by IL-10. J. Immunol. 169, 2253-2263 (2002).
122. Williams, L.M., Ricchetti, G., Sarma, U., Smallie, T. & Foxwell, B.M. Interleukin-10 suppression of myeloid cell activation-a continuing puzzle. Immunology 113, 281-292 (2004).
123. Sabat, R. et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 21, 331-344 (2010).
124. Uno, J.K. et al. Altered macrophage function contributes to colitis inmice defective in the phosphoinositide-3 kinase subunit p110delta. Gastroenterology 139, 1642-1653. 1653 e1-6 (2010).
125. Chaurasia, B. et al. Phosphoinositide-dependent kinase 1 provides negative feedback inhibition to Toll-like receptor-mediated NF-kappaB activation in macrophages. Mol. Cell Biol. 30, 4354-4366 (2010).
126. Hedl, M. & Abraham, C. Secretory mediators regulate Nod2-induced tolerance in human macrophages. Gastroenterology 140, 231-241 (2011).
127. Guha, M. &Mackman,N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J. Biol. Chem. 277, 32124-32132 (2002).
128. Fukao, T. et al. PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat. Immunol. 3, 875-881 (2002).
129. Martin, M. et al. Role of the phosphatidylinositol 3 kinase-Akt pathway in the regulation of IL-10 and IL-12 by Porphyromonas gingivalis lipopolysaccharide. J. Immunol. 171, 717-725 (2003).
130. Gonzalez-Garcia, A., Sanchez-Ruiz, J., Flores, J.M. & Carrera, A.C. Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer. Gastroenterology 138, 1374-1383 (2010).
131. Jarry, A. et al. Mucosal IL-10 and TGF-beta play crucial roles in preventing LPS-driven, IFN-gamma-mediated epithelial damage in human colon explants. J. Clin. Invest. 118, 1132-1142 (2008).
132. Elson, C.O. et al. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol. Rev. 206, 260-276 (2005).
133. Watanabe, N. et al. Elimination of local macrophages in intestine prevents chronic colitis in interleukin-10-deficient mice. Dig. Dis. Sci. 48, 408-414 (2003).
134. Murai, M. et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat. Immunol. 10, 1178-1184 (2009).
135. Rani, R., Smulian, A.G., Greaves, D.R., Hogan, S.P. & Herbert, D.R. TGF-beta limits IL-33 production and promotes the resolution of colitis through regulation of macrophage function. Eur. J. Immunol. 41, 2000-2009 (2011).
136. Smythies, L.E. et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J. Clin. Invest. 115, 66-75 (2005).
137. Glocker, E.O. et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361, 2033-2045 (2009).
138. Glocker, E.O. et al. Infant colitis-it's in the genes. Lancet 376, 1272 (2010).
139. Gabay, C., Lamacchia,C. & Palmer,G. IL-1 pathways in inflammation and human diseases. Nat. Rev. Rheumatol. 6, 232-241 (2010).
140. Hedl, M. & Abraham, C. Distinct roles for Nod2 protein and autocrine interleukin-1{beta} in muramyl dipeptide-induced mitogen-activated protein kinase activation and cytokine secretion in human macrophages. J. Biol. Chem. 286, 26440-26449 (2011).
141. Ferretti, M. et al. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J. Clin. Invest. 94, 449-453 (1994).
142. Hirsch, E., Irikura, V.M., Paul, S.M. & Hirsh, D. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc. Natl. Acad. Sci. USA 93, 11008-11013 (1996).
143. Kastner, D.L., Aksentijevich, I. & Goldbach-Mansky, R. Autoinflammatory disease reloaded: a clinical perspective. Cell 140, 784-790 (2011).
144. Katakura, K. et al. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J. Clin. Invest. 115, 695-702 (2005).
145. Kollias, G., Douni, E., Kassiotis, G. & Kontoyiannis, D. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol. Rev. 169, 175-194 (1999).
146. Jacob, C.O. & McDevitt, H.O. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 331, 356-358 (1988).
147. Hommes, D. et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122, 7-14 (2002).
148. Roncarolo, M.G. & Battaglia, M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat. Rev. Immunol. 7, 585-598 (2007).
149. Yi, A.K. et al. Role of mitogen-activated protein kinases in CpG DNAmediated IL-10 and IL-12 production: central role of extracellular signalregulated kinase in the negative feedback loop of theCpGDNA-mediated Th1 response. J. Immunol. 168, 4711-4720 (2002).
150. Lucas, M., Zhang, X., Prasanna, V. & Mosser, D.M. ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus. J. Immunol. 175, 469-477 (2005).
151. Foey, A.D. et al. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases. J. Immunol. 160, 920-928 (1998).
152. Ma, W. et al. The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. J. Biol. Chem. 276, 13664-13674 (2001).
153. Hedl, M. & Abraham, C. Nod2-induced autocrine interleukin-1 alters signaling by ERK and p38 to differentially regulate secretion of inflammatory cytokines. Gastroenterology 143, 1530-1543 (2012).
154. Papoutsopoulou, S. et al. ABIN-2 is required for optimal activation of Erk MAP kinase in innate immune responses. Nat. Immunol. 7, 606-615 (2006).
155. Strassheim, D. et al. Phosphoinositide 3-kinase and Akt occupy central roles in inflammatory responses of Toll-like receptor 2-stimulated neutrophils. J. Immunol. 172, 5727-5733 (2004).
156. Ojaniemi, M. et al. Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur. J. Immunol. 33, 597-605 (2003).
157. Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M. & Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11, 329-341 (2010).
158. Barber, D.F. et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 11, 933-935 (2005).
159. Camps, M. et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11, 936-943 (2005).
160. Ohtani, M. et al. Cutting edge: mTORC1 in intestinal CD11c+CD11b+ dendritic cells regulates intestinal homeostasis by promoting IL-10 production. J. Immunol. 188, 4736-4740 (2012).
161. O'Neill, L.A., Sheedy, F.J. & McCoy, C.E. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat. Rev. Immunol. 11, 163-175 (2011).
162. Taganov, K.D., Boldin, M.P., Chang, K.J. & Baltimore, D. NF-kappaBdependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA 103, 12481-12486 (2006).
163. Lofgren, S.E. et al. Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene. Genes Immun. 13, 268-274 (2012).
164. Zhu, S. et al. The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-alpha. Nat. Med. 18, 1077-1086 (2011).
165. Kurowska-Stolarska, M. et al. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc. Natl. Acad. Sci. USA 108, 11193-11198 (2010).
166. Fabbri, M. et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. USA 109, E2110-E2116 (2012).
167. Wu, F. et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology 135, 1624-1635. e24 (2008).
168. Chatzikyriakidou, A., Voulgari, P.V., Georgiou, I. & Drosos, A.A. miRNAs and related polymorphisms in rheumatoid arthritis susceptibility. Autoimmun. Rev. 11, 636-641 (2011).
169. Rossi, R.L. et al. Distinct microRNA signatures in human lymphocyte subsets and enforcement of the naive state in CD4+ T cells by the microRNA miR-125b. Nat. Immunol. 12, 796-803 (2011).
170. Kobayashi, T. et al. IL-10 Regulates Il12b Expression via Histone Deacetylation: Implications for Intestinal Macrophage Homeostasis. J. Immunol. 189, 1792-1799 (2012).
171. Yoza, B.K., Hu, J.Y. & McCall, C.E. Inhibition of histone deacetylation enhances endotoxin-stimulated transcription but does not reverse endotoxin tolerance. J. Endotoxin Res. 8, 109-114 (2002).
172. Huang, Y. et al. Global mapping of H3K4me3 and H3K27me3 reveals chromatin state-based regulation of human monocyte-derived dendritic cells in different environments. Genes Immun. 13, 311-320 (2012).
173. El Gazzar, M. et al. Chromatin-specific remodeling by HMGB1 and linker histone H1 silences proinflammatory genes during endotoxin tolerance. Mol. Cell Biol. 29, 1959-1971 (2009).
174. Chan, C., Li, L., McCall, C.E. & Yoza, B.K. Endotoxin tolerance disrupts chromatin remodeling and NF-kappaB transactivation at the IL-1beta promoter. J. Immunol. 175, 461-468 (2005).
175. Nimmo, E.R. et al. TLE1 modifies the effects of NOD2 in the pathogenesis of Crohn's disease. Gastroenterology 141, 972-981. e1-2 (2011).
176. Glauben, R. et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 176, 5015-5022 (2006).
177. Mishra, N., Reilly, C.M., Brown, D.R., Ruiz, P. & Gilkeson, G.S. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest. 111, 539-552 (2003).
178. Vojinovic, J. & Damjanov, N. HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Mol. Med. 17, 397-403 (2011).
179. Edwards, A.J. & Pender, S.L. Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases. Biochem. Soc. Trans. 39, 1092-1095 (2011).
180. Dinarello, C.A., Fossati, G. & Mascagni, P. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol. Med. 17, 333-352 (2011).
181. Franchi, L., Eigenbrod, T., Munoz-Planillo, R. & Nunez, G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat. Immunol. 10, 241-247 (2009).
182. Mariathasan, S. et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430, 213-218 (2004).
183. Siegmund, B., Lehr, H.A., Fantuzzi, G. & Dinarello, C.A. IL-1 beta - converting enzyme (caspase-1) in intestinal inflammation. Proc. Natl. Acad. Sci. USA 98, 13249-13254 (2001).
184. Carvalho, F.A. et al. Cytosolic flagellin receptor NLRC4 protects mice againstmucosal and systemic challenges. Mucosal Immunol. 5, 288-298 (2012).
185. Elinav, E. et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145, 745-757 (2011).
186. Hoffman, H.M., Mueller, J.L., Broide, D.H., Wanderer, A.A. & Kolodner, R.D. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat. Genet. 29, 301-305 (2001).
187. Feldmann, J. et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am. J. Hum. Genet. 71, 198-203 (2002).
188. Consortium, T.I.F. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 90, 797-807 (1997).
189. Dieude, P. et al. NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosisrelated fibrosing alveolitis pathogenesis. Ann. Rheum. Dis. 70, 668-674 (2011).
190. Jin, Y. et al. NALP1 in vitiligo-associated multiple autoimmune disease. N. Engl. J. Med. 356, 1216-1225 (2007).
191. Hugot, J.P. et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599-603 (2001).
192. Ogura, Y. et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603-606 (2001).
193. Vladimer, G.I. et al. The NLRP12 inflammasome recognizes Yersinia pestis. Immunity 37, 96-107 (2012).
194. Lich, J.D. et al. Monarch-1 suppresses non-canonical NF-kappaB activation and p52-dependent chemokine expression in monocytes. J. Immunol. 178, 1256-1260 (2007).
195. Williams, K.L. et al. The CATERPILLER protein monarch-1 is an antagonist of toll-like receptor-, tumor necrosis factor alpha-, and Mycobacterium tuberculosis-induced pro-inflammatory signals. J. Biol. Chem. 280, 39914-39924 (2005).
196. Allen, I.C. et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-kappaB signaling. Immunity 36, 742-754 (2012).
197. Allen, I.C. et al. Characterization of NLRP12 during the Development of Allergic Airway Disease in Mice. PLoS One 7, e306122012).
198. Borghini, S. et al. Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation. Arthritis Rheum. 63, 830-839 (2011).
199. Jeru, I. et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc. Natl. Acad. Sci. USA 105, 1614-1619 (2008).
200. Macaluso, F. et al. Polymorphisms in NACHT-LRR (NLR) genes in atopic dermatitis. Exp. Dermatol. 16, 692-698 (2007).
201. Dinarello, C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117, 3720-3732 (2011).
202. Delgado, M. et al. Autophagy and pattern recognition receptors in innate immunity. Immunol. Rev. 227, 189-202 (2009).
203. Travassos, L.H. et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat. Immunol. 11, 55-62 (2010).
204. McCarroll, S.A. et al. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat. Genet. 40, 1107-1112 (2008).
205. Cadwell, K. et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456, 259-263 (2008).
206. Cooney, R. et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat. Med. 16, 90-97 (2010).
207. Homer, C.R., Richmond, A.L., Rebert, N.A., Achkar, J.P. & McDonald, C. ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis. Gastroenterology 139, 1630-1641. 1641 e1-2 (2010).
208. Parkes, M. et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat. Genet. 39, 830-832 (2007).
209. Brest, P. et al. A synonymous variant in IRGM alters a binding site formiR- 196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nat. Genet. 43, 242-245 (2011).
210. Glubb, D.M. et al. NOD2 and ATG16L1 polymorphisms affect monocyte responses in Crohn's disease. World J. Gastroenterol. 17, 2829-2837 (2011).
211. Cadwell, K. et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell 141, 1135-1145 (2010).
212. Hwang, S. et al. Nondegradative role of Atg5-Atg12/Atg16L1 autophagy protein complex in antiviral activity of interferon gamma. Cell Host Microbe 11, 397-409 (2012).
213. Shi, C.S. et al. Activation of autophagy by inflammatory signals limits IL-1beta production by targeting ubiquitinated inflammasomes for destruction. Nat. Immunol. 13, 255-263 (2011).
214. Nakahira, K. et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat. Immunol. 12, 222-230 (2011).
215. Saitoh, T. et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 456, 264-268 (2008).
216. Plantinga, T.S. et al. Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut 60, 1229-1235 (2011).
217. Lee, S.H., Starkey, P.M. & Gordon, S. Quantitative analysis of total macrophage content in adult mouse tissues. Immunochemical studies with monoclonal antibody F4/80. J. Exp. Med. 161, 475-489 (1985).
218. Mowat, A.M. & Bain, C.C. Mucosal macrophages in intestinal homeostasis and inflammation. J. Innate Immun. 3, 550-564 (2011).
219. Denning, T.L., Wang, Y.C., Patel, S.R., Williams, I.R. & Pulendran, B. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat. Immunol. 8, 1086-1094 (2007).
220. Franchi, L. et al. NLRC4-driven production of IL-1beta discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat. Immunol. 13, 449-456 (2012).
221. Mazmanian, S.K., Round, J.L. &Kasper,D.L. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453, 620-625 (2008).
222. Platt, A.M., Bain, C.C., Bordon, Y., Sester, D.P. & Mowat, A.M. An independent subset of TLR expressing CCR2-dependent macrophages promotes colonic inflammation. J. Immunol. 184, 6843-6854 (2010).
223. Kim, Y.G. et al. The Nod2 sensor promotes intestinal pathogen eradication via the chemokine CCL2-dependent recruitment of inflammatory monocytes. Immunity 34, 769-780 (2011).
224. Rivollier, A., He, J., Kole, A., Valatas, V. & Kelsall, B.L. Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon. J. Exp. Med. 209, 139-155 (2012).
225. Waddell, A. et al. Colonic eosinophilic inflammation in experimental colitis is mediated by Ly6C(high) CCR2(+) inflammatory monocyte/macrophage- derived CCL11. J. Immunol. 186, 5993-6003 (2011).
226. Shi, Y., Evans, J.E. & Rock, K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425, 516-521 (2003).
227. Bogunovic, M. et al. Origin of the lamina propria dendritic cell network. Immunity 31, 513-525 (2009).
228. Kamada, N. et al. Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria. J. Immunol. 175, 6900-6908 (2005).
229. Varol, C. et al. Intestinal lamina propria dendritic cell subsets have different origin and functions. Immunity 31, 502-512 (2009).
230. Dunay, I.R. et al. Gr1(+) inflammatory monocytes are required for mucosal resistance to the pathogen Toxoplasma gondii. Immunity 29, 306-317 (2008).
231. Shiloh, M.U. et al. Phenotype of mice and macrophages deficient in both phagocyte oxidase and inducible nitric oxide synthase. Immunity 10, 29-38 (1999).
232. Annacker, O. et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J. Exp. Med. 202, 1051-1061 (2005).
233. Siddiqui, K.R., Laffont, S. & Powrie, F. E-cadherin marks a subset of inflammatory dendritic cells that promote Tcell-mediated colitis. Immunity 32, 557-567 (2011).
234. Manicassamy, S. et al. Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science 329, 849-853 (2010).
235. Medina-Contreras, O. et al. CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice. J. Clin. Invest. 121, 4787-4795 (2011).
236. Bain, C.C. et al. Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6C(hi) monocyte precursors. Mucosal Immunol. advance online publication, 19 September 2012; doi: 10.1038/mi.2012.89 (2012).
237. Kamada, N. et al. Human CD14+ macrophages in intestinal lamina propria exhibit potent antigen-presenting ability. J. Immunol. 183, 1724-1731 (2009).
238. Kamada, N. et al. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J. Clin. Invest. 118, 2269-2280 (2008).
239. Bimczok, D. et al. Stromal regulation of human gastric dendritic cells restricts the Th1 response to Helicobacter pylori. Gastroenterology 141, 929-938 (2011).
240. Maheshwari, A. et al. TGF-beta2 suppresses macrophage cytokine production and mucosal inflammatory responses in the developing intestine. Gastroenterology 140, 242-253 (2011).
241. Iliev, I.D., Mileti, E., Matteoli, G., Chieppa, M. & Rescigno, M. Intestinal epithelial cells promote colitis-protective regulatory T-cell differentiation through dendritic cell conditioning. Mucosal Immunol. 2, 340-350 (2009).
242. Taylor, B.C. et al. TSLP regulates intestinal immunity and inflammation in mouse models of helminth infection and colitis. J. Exp. Med. 206, 655-667 (2009).
243. Ramalingam, R. et al. Dendritic cell-specific disruption of TGF-beta receptor II eads to altered regulatory T cell phenotype and spontaneous multiorgan autoimmunity. J. Immunol. 189, 3878-3893 (2012).
244. Sadeghi, K. et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur. J. Immunol. 36, 361-370 (2006).
245. Alex, P. et al. Clcn5 knockout mice exhibit novel immunomodulatory effects and are more susceptible to dextran sulfate sodium-induced colitis. J. Immunol. 184, 3988-3996 (2010).
246. Cantorna, M.T., Munsick, C., Bemiss, C. & Mahon, B.D. 1,25- Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J. Nutr. 130, 2648-2652 (2000).
247. Ananthakrishnan, A.N. et al. Higher Predicted Vitamin D Status Is Associated With Reduced Risk of Crohn's Disease. Gastroenterology 142, 482-489 (2011).
248. Raftery, T., O'Morain, C. & O'Sullivan, M. Vitamin D: new Roles and Therapeutic Potential in Inflammatory Bowel Disease. Curr. Drug Metab. 13, 1294-1302 (2012).
249. Ulitsky, A. et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. J. Parenter. Enteral. Nutr. 35, 308-316 (2011).
250. Hall, J.A., Grainger, J.R., Spencer, S.P. & Belkaid, Y. The role of retinoic acid in tolerance and immunity. Immunity 35, 13-22 (2011).
251. Zapata-Gonzalez, F. et al. 9-cis-Retinoic acid (9cRA), a retinoid X receptor (RXR) ligand, exerts immunosuppressive effects on dendritic cells by RXR-dependent activation: inhibition of peroxisome proliferator-activated receptor gamma blocks some of the 9cRA activities, and precludes them to mature phenotype development. J. Immunol. 178, 6130-6139 (2007).
252. Voll, R.E. et al. Immunosuppressive effects of apoptotic cells. Nature 390, 350-351 (1997).
253. Fadok, V.A. et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J. Clin. Invest. 101, 890-898 (1998).
254. Chen, W., Frank, M.E., Jin, W. & Wahl, S.M. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 14, 715-725 (2001).
255. Hanayama, R. et al. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science 304, 1147-1150 (2004).
256. Botto, M. et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 19, 56-59 (1998).
257. Rodriguez-Manzanet, R. et al. TandBcell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proc.Natl. Acad. Sci. USA 107, 8706-8711 (2010).
258. Kuballa, P., Nolte, W.M., Castoreno, A.B. & Xavier, R.J. Autophagy and the immune system. Annu. Rev. Immunol. 30, 611-646 (2012).
259. Liu, P.T. et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311, 1770-1773 (2006).
260. Adams, J.S. et al. Vitamin D-directed rheostatic regulation of monocyte antibacterial responses. J. Immunol. 182, 4289-4295 (2009).
261. Smith, A.M. et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J. Exp. Med. 206, 1883-1897 (2009).
262. Rioux, J.D. et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat. Genet. 39, 596-604 (2007).
263. Kim, Y.G. et al. The cytosolic sensors Nod1 and Nod2 are critical for bacterial recognition and host defense after exposure to Toll-like receptor ligands. Immunity 28, 246-257 (2008).
264. Kapetanovic, R. et al. Contribution of phagocytosis and intracellular sensing for cytokine production by Staphylococcus aureus-activated macrophages. Infect. Immun. 75, 830-837 (2007).
265. Magalhaes, J.G. et al. Murine Nod1 but not its human orthologue mediates innate immune detection of tracheal cytotoxin. EMBO Rep. 6, 1201-1207 (2005).
266. Li, J. et al. Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15mutations. Hum. Mol. Genet. 13, 1715-1725 (2004).
267. Netea, M.G. et al. The frameshift mutation in Nod2 results in unresponsiveness not only to Nod2- but also Nod1-activating peptidoglycan agonists. J. Biol. Chem. 280, 35859-35867 (2005).
268. Nahori, M.A. et al. Differential TLR recognition of leptospiral lipid A and lipopolysaccharide in murine and human cells. J. Immunol. 175, 6022-6031 (2005).
269. Krausgruber, T. et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 12, 231-238 (2011).
270. Martinez, F.O., Gordon, S., Locati, M. & Mantovani, A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 177, 7303-7311 (2006).
271. Lacey, D.C. et al. Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models. J. Immunol. 188, 5752-5765 (2012).
272. Richez, C. et al. Role for interferon regulatory factors in autoimmunity. Joint Bone Spine 77, 525-531 (2010).
273. Hedl, M. & Abraham, C. IRF5 risk polymorphisms contribute to interindividual variance in pattern recognition receptor-mediated cytokine secretion in human monocyte-derived cells. J. Immunol. 1882012).
274. Xu,H. et al. Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization. Nat. Immunol. 13, 642-650 (2012).
275. Carta, S. et al. The rate of interleukin-1beta secretion in different myeloid cells varies with the extent of redox response to Toll-like receptor triggering. J. Biol. Chem. 286, 27069-27080 (2011).
276. Qu, Y., Franchi, L., Nunez, G. & Dubyak, G.R. Nonclassical IL-1 beta secretion stimulated by P2-7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J. Immunol. 179, 1913-1925 (2007).
277. Pelegrin, P., Barroso-Gutierrez, C. & Surprenant, A. P2-7 receptor differentially couples to distinct release pathways for IL-1beta in mouse macrophage. J. Immunol. 180, 7147-7157 (2008).
278. Tang, D., Kang, R., Coyne, C.B., Zeh, H.J. & Lotze, M.T. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol. Rev. 249, 158-175 (2012).
279. Mariathasan, S. et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440, 228-232 (2006).
280. Piccini, A. et al. ATP is released by monocytes stimulated with pathogensensing receptor ligands and induces IL-1beta and IL-18 secretion in an autocrine way. Proc. Natl. Acad. Sci. USA 105, 8067-8072 (2008).
281. Netea, M.G. et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 113, 2324-2335 (2009).
282. Seshadri, S., Duncan, M.D., Hart, J.M., Gavrilin, M.A. & Wewers, M.D. Pyrin levels in human monocytes and monocyte-derived macrophages regulate IL-1beta processing and release. J. Immunol. 179, 1274-1281 (2007).
283. Ward, J.R. et al. Temporal interleukin-1beta secretion from primary human peripheral blood monocytes by P2-7-independent and P2-7-dependent mechanisms. J. Biol. Chem. 285, 23147-23158 (2011).
284. Cheung, R., Ravyn, V., Wang, L., Ptasznik, A. & Collman, R.G. Signaling mechanism of HIV-1 gp120 and virion-induced IL-1beta release in primary human macrophages. J. Immunol. 180, 6675-6684 (2008).
285. Chen, H., Cowan, M.J., Hasday, J.D., Vogel, S.N. & Medvedev, A.E. Tobacco smoking nhibits expression of proinflammatory cytokines and activation of IL-1R-associated kinase, p38, and NF-kappaB in alveolar macrophages stimulated with TLR2 and TLR4 agonists. J. Immunol. 179, 6097-6106 (2007).
286. Novikov, A. et al. Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1beta production in human macrophages. J. Immunol. 187, 2540-2547 (2011).
287. Vogt, G. & Nathan, C. In vitro differentiation of human macrophages with enhanced antimycobacterial activity. J. Clin. Invest. 121, 3889-3901 (2012).
288. Chapman, S.J. & Hill, A.V. Human genetic susceptibility to infectious disease. Nat Rev Genet 13, 175-188 (2012).
289. Le Moine, O. et al. Role of defective monocyte interleukin-10 release in tumor necrosis factor-alpha overproduction in alcoholics cirrhosis. Hepatology 22, 1436-1439 (1995).
290. Gleeson, M. et al. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat. Rev. Immunol. 11, 607-615 (2011).
291. Yang, L. et al. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology 137, 588-597 (2009).
292. Barnich, N. et al. CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization inCrohn disease. J. Clin. Invest. 117, 1566-1574 (2007).
293. Garrett, W.S., Gordon, J.I. & Glimcher, L.H. Homeostasis and inflammation in the intestine. Cell 140, 859-870 (2010).
294. Ley, R.E., Turnbaugh, P.J., Klein, S. & Gordon, J.I. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022-1023 (2006).
295. Jacob, C.O. et al. Heritable major histocompatibility complex class IIassociated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 87, 1233-1237 (1990).
296. Panda, A. et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J. Immunol. 184, 2518-2527 (2010).
297. Wurfel, M.M. et al. Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am. J. Respir. Crit. Care Med. 178, 710-720 (2008).
298. Wurfel, M.M. et al. Identification of high and low responders to lipopolysaccharide in normal subjects: an unbiased approach to identify modulators of innate immunity. J. Immunol. 175, 2570-2578 (2005).
299. Vamvakopoulos, J., Green, C. & Metcalfe, S. Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist. Eur. J. Immunol. 32, 2988-2996 (2002).
300. vonBernuth, H. et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 321, 691-696 (2008).
301. Sancho-Shimizu, V. et al. Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J. Clin. Invest. 121, 4889-4902 (2011).
302. Arnott, I.D. et al. NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe?. Genes Immun. 5, 417-425 (2004).
303. Bonen, D.K. et al. Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 124, 140-146 (2003).
304. Ferwerda, B. et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc. Natl. Acad. Sci. USA 104, 16645-16650 (2007).
305. Schadt, E.E. Molecular networks as sensors and drivers of common human diseases. Nature 461, 218-223 (2009).
306. Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179-185 (2012).
307. Garrett, W.S. et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 131, 33-45 (2007).
308. Maslowski, K.M. et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461, 1282-1286 (2009).
309. Shultz, L.D., Brehm, M.A., Garcia-Martinez, J.V. & Greiner, D.L. Humanized mice for immune system investigation: progress, promise and challenges. Nat. Rev. Immunol. 12, 786-798 (2012).
310. Karban, A.S. et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum. Mol. Genet. 13, 35-45 (2004).
311. Garlanda, C., Anders, H.J. & Mantovani, A. TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol. 30, 439-446 (2009).
312. Chen, X., Zhao, Y., Wu, X. & Qian, G. Enhanced expression of single immunoglobulin IL-1 receptor-related molecule ameliorates LPS-induced acute lung injury in mice. Shock 35, 198-204 (2011).
313. Wald, D. et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat. Immunol. 4, 920-927 (2003).
314. Garlanda, C. et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc. Natl. Acad. Sci. USA 101, 3522-3526 (2004).
315. Lech, M. et al. Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J. Exp. Med. 205, 1879-1888 (2008).
316. Horne, D.J. et al. Common polymorphisms in the PKP3-SIGIRRTMEM16J gene region are associated with susceptibility to tuberculosis. J. Infect. Dis. 205, 586-594 (2012).
317. Adib-Conquy, M. et al. Up-regulation of MyD88s and SIGIRR, molecules inhibiting Toll-like receptor signaling, in monocytes from septic patients. Crit. Care Med. 34, 2377-2385 (2006).
318. Mitsuzawa, H. et al. Recombinant soluble forms of extracellular TLR4 domain and MD-2 inhibit lipopolysaccharide binding on cell surface and dampen lipopolysaccharide-induced pulmonary inflammation in mice. J. Immunol. 177, 8133-8139 (2006).
319. Raby, A.C. et al. Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. J. Immunol. 183, 506-517 (2009).
320. Gazouli, M. et al. Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. World J. Gastroenterol. 11, 681-685 (2005).
321. Lakatos, P.L. et al. Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease. Inflamm. Bowel Dis. 17, 767-777 (2012).
322. Spencer, S.D. et al. The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J. Exp. Med. 187, 571-578 (1998).
323. Mauro, C. et al. ABIN-1 binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-kappaB. J Biol Chem 281, 18482-18488 (2006).
324. Gao, L. et al. ABIN1 protein cooperates with TAX1BP1 and A20 proteins to inhibit antiviral signaling. J. Biol. Chem. 286, 36592-36602 (2011).
325. Zhou, J. et al. A20-binding inhibitor of NF-kappaB (ABIN1) controls Tolllike receptor-mediated CCAAT/enhancer-binding protein beta activation and protects from inflammatory disease. Proc. Natl. Acad. Sci. USA 108, E998-1006 (2011).
326. Nanda, S.K. et al. Polyubiquitin binding to ABIN1 is required to prevent autoimmunity. J. Exp. Med. 208, 1215-1228 (2011).
327. El Bakkouri, K., Wullaert, A., Haegman, M., Heyninck, K. & Beyaert, R. Adenoviral gene transfer of the NF-kappa B inhibitory protein ABIN-1 decreases allergic airway inflammation in a murine asthma model. J. Biol. Chem. 280, 17938-17944 (2005).
328. Wullaert, A. et al. Adenoviral gene transfer of ABIN-1 protects mice from TNF/galactosamine-induced acute liver failure and lethality. Hepatology 42, 381-389 (2005).
329. Gateva, V. et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat. Genet. 41, 1228-1233 (2009).
330. Han, J.W. et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat. Genet. 41, 1234-1237 (2009).
331. Wullaert, A. et al. LIND/ABIN-3 is a novel lipopolysaccharide-inducible inhibitor of NF-kappaB activation. J. Biol. Chem. 282, 81-90 (2007).
332. Mashima, R. et al. FLN29, a novel interferon- and LPS-inducible gene acting as a negative regulator of toll-like receptor signaling. J. Biol. Chem. 280, 41289-41297 (2005).
333. Sanada, T. et al. FLN29 deficiency reveals its negative regulatory role in the Toll-like receptor (TLR) and retinoic acid-inducible gene I (RIG-I)-like helicase signaling pathway. J. Biol. Chem. 283, 33858-33864 (2008).
334. Chi, H. et al. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc. Natl. Acad. Sci. USA 103, 2274-2279 (2006).
335. Matta, R. et al. Knockout of Mkp-1 exacerbates colitis in Il-10-deficient mice. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G1322-G1335 (2012).
336. Frazier, W.J. et al. Increased inflammation, impaired bacterial clearance, and metabolic disruption after gram-negative sepsis in Mkp-1-deficient mice. J. Immunol. 183, 7411-7419 (2009).
337. Bhavsar, P. et al. Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma. Thorax 63, 784-790 (2008).
338. Rastogi, R. et al. Dysregulation of p38 and MKP-1 in response to NOD1/TLR4 stimulation in sarcoid bronchoalveolar cells. Am. J. Respir. Crit. Care Med. 183, 500-510 (2011).
339. Burns, K. et al. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med. 197, 263-268 (2003).
340. Zaki, M.H. et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell 20, 649-660 (2011).
341. Hubbard, L.L. et al. A role for IL-1 receptor-associated kinase-M in prostaglandin E2-induced immunosuppression post-bone marrow transplantation. J. Immunol. 184, 6299-6308 (2010).
342. Aronoff, D.M., Canetti, C. & Peters-Golden, M. Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptormediated increase in intracellular cyclic AMP. J. Immunol. 173, 559-565 (2004).
343. Serezani, C.H. et al. Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. Am. J. Respir. Cell Mol. Biol. 37, 562-570 (2007).
344. Kabashima, K. et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J. Clin. Invest. 109, 883-893 (2002).
345. Morteau, O. et al. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J. Clin. Invest. 105, 469-478 (2000).
346. Chong, M.M., Metcalf, D., Jamieson, E., Alexander, W.S. & Kay, T.W. Suppressor of cytokine signaling-1 in T cells and macrophages is critical for preventing lethal inflammation. Blood 106, 1668-1675 (2005).
347. Mottok, A., Renne, C.,Willenbrock, K., Hansmann, M.L. & Brauninger, A. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood 110, 3387-3390 (2007).
348. Berlato, C. et al. Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation. J. Immunol. 168, 6404-6411 (2002).
349. Croker, B.A. et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4, 540-545 (2003).
350. Roberts, A.W. et al. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc. Natl. Acad. Sci. USA 98, 9324-9329 (2001).
351. Yasukawa, H. et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 4, 551-556 (2003).
352. Schreiber, S. et al. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 51, 379-385 (2002).
353. Bulut, Y., Faure, E., Thomas, L., Equils, O. & Arditi, M. Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J. Immunol. 167, 987-994 (2001).
354. Zhang, G. & Ghosh, S. Negative regulation of toll-like receptor-mediated signaling by Tollip. J. Biol. Chem. 277, 7059-7065 (2002).
355. Burns, K. et al. Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat. Cell. Biol. 2, 346-351 (2000).
356. Didierlaurent, A. et al. Tollip regulates proinflammatory responses to interleukin-1 and lipopolysaccharide. Mol. Cell Biol. 26, 735-742 (2006).
357. Schimming, T.T. et al. Association of toll-interacting protein gene polymorphisms with atopic dermatitis. BMC Dermatol. 7, 3 (2007).
358. Shah, J.A. et al. Human TOLLIP regulates TLR2 and TLR4 signaling and its polymorphisms are associated with susceptibility to tuberculosis. J. Immunol. 189, 1737-1746 (2012).
359. Sosic, D., Richardson, J.A., Yu, K., Ornitz, D.M. & Olson, E.N. Twist regulates cytokine gene expression through a negative feedback loop that represses NF-kappaB activity. Cell 112, 169-180 (2003).
360. Sharabi, A.B. et al. Twist-2 controls myeloid lineage development and function. PLoS Biol. 6, e3162008).
361. Chen, Z.F. & Behringer, R.R. twist is required in head mesenchyme for cranial neural tube morphogenesis. Genes Dev. 9, 686-699 (1995).
362. Niesner, U. et al. Autoregulation of Th1-mediated inflammation by twist1. J. Exp. Med. 205, 1889-1901 (2008).